Daratumumab by subcutaneous injection was authorised in 2021 as an addition to the combination of pomalidomide + dexamethasone for some multiple myeloma patients who had already received one or more lines of chemotherapy. In one open-label trial including about 300 patients with refractory or relapsed multiple myeloma (who had received at least lenaUdomide or a proteasome inhibitor), disease progression was less frequent with addition of daratumumab to the pomalido-mide + dexamethasone protocol than without. Mortality did not differ between the groups. Serious adverse effects were more frequent in the daratumumab group, with syncope added to its adverse effects.
展开▼
